<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675207</url>
  </required_header>
  <id_info>
    <org_study_id>NWOIADJ 2006</org_study_id>
    <nct_id>NCT00675207</nct_id>
  </id_info>
  <brief_title>Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs</brief_title>
  <official_title>Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern Ophthalmic Institute S.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern Ophthalmic Institute S.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and
      brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy
      (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Measurements at peak and trough effect (10 am and 4 pm) at baseline, month 1, and month 4</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine purite 0.15%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dorzolamide 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brinzolamide 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine purite 0.15%</intervention_name>
    <description>A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alphagan P 0.15%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzolamide 2%</intervention_name>
    <description>A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Trusopt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 1%</intervention_name>
    <description>A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Azopt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension.

          -  Must be over 40 years of age.

          -  Intraocular pressure must be 18 mm Hg or higher after 6 weeks of treatment (run-in)
             with a prostaglandin analog (bimatoprost, latanoprost, or travoprost).

        Exclusion Criteria:

          -  History of angle closure or narrow angle.

          -  Previous intraocular surgery.

          -  Laser trabeculoplasty within 3 months prior to screening.

          -  History of uveitis or intraocular inflammation.

          -  Use of medications other than the study medications that are known to affect IOP
             (e.g., beta-blockers, steroids, or angiotensin II blockers) within 3 months of study
             entry or during the study.

          -  Intolerance of or hypersensitivity to prostaglandin analogs, sulfonamides,
             alpha-agonists, or the preservative benzalkonium chloride.

          -  Women of childbearing age who are pregnant or not using contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E. Bournias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Ophthalmic Institute S.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Ophthalmic Institute S.C.</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Thomas E. Bournias</name_title>
    <organization>Northwestern Ophthalmic Institute S.C.</organization>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>adjunctive treatment</keyword>
  <keyword>prostaglandin</keyword>
  <keyword>prostaglandin analog</keyword>
  <keyword>brimonidine</keyword>
  <keyword>dorzolamide</keyword>
  <keyword>brinzolamide</keyword>
  <keyword>alpha agonist</keyword>
  <keyword>carbonic anhydrase inhibitor</keyword>
  <keyword>intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

